Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 353 participants.
Also called NCT02330406
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 353 participants
- Sponsor
- Institute for Clinical Effectiveness, Japan
- Registry
-
NCT02330406
-
- Other papers using this trial's data
- Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial
- Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial
- Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02330406. Randomized; double masking; primary purpose treatment. Start 2015-04 (actual); primary completion 2018-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial
- Acronym
- REASON
- Condition
- Dipeptidyl-Peptidase 4 Inhibitors
- Condition
- LDL Cholesterol
- Condition
- Glycosylated Hemoglobin
- Condition
- Diabetes Mellitus
- Condition
- Coronary Disease
- Intervention (Drug)
- Anagliptin
- Intervention (Drug)
- Sitagliptin
- Lead sponsor
- Institute for Clinical Effectiveness, Japan
Record details
- Record id
cardio:ct-nct02330406- Content hash
799da9da55cb83255b92cfc291d2abd1df6988a8193ee59f4a4c2ce66224ab27